Drugs / SAR444881
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04717375 | Apr 2021 → Jul 2025 | cancer | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT06651593 | Jul 2025 → Sep 2028 expected | cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-31 | Biond Biologics | Biond Biologics Announces a Joint Poster Presentation With Sanofi at The ASCO 2022 Annual Meeting Presenting Pre-Clinical Translational Data of SAR444881 (BND-22) biondbio.com ↗ |
| 2022-05-23 | Biond Biologics | Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial biondbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR444881 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06651593 ↗ |
| Route | Intravenous | “SAR444881 will be administered intravenously (IV), every 2 weeks (Q2W).” NCT04717375 ↗ |